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Introduction Minimally invasive methods for injured ligament and tendon restoration have been devel-
oped and gained popularity in recent years. Injury and relaxation of the pubourethral ligament (PUL) can 
lead to stress urinary incontinence (SUI). The aim of this study was to investigate the impact of injecting 
platelet rich plasma (PRP) into the PUL following its surgical transection resulting in SUI, confirmed by 
leak point pressure (LPP) measurements pre- and post-intervention in an experimental animal model.
Material and methods Twenty female adult Sprague-Dawley rats were assigned in 2 groups: 1) treat-
ment group with transection of the PUL and application of PRP at the time of transection and at one 
month follow-up and 2) a control group, with transection of the PUL only. Leak point pressures (LPPs) 
were measured prior to transection, immediately following the transection and at 1 and 2 months in 
both groups.
Results The median LPPs for the control group were: LPP – preT: 35.6 (29.8–44.8) cmH2O, LPP – postT: 
14.6 (5.8–19.0) cmH2O, LPP – 1 month: 27.3 (19.2–33.8) cmH2O, LPP – 2 months: 29.0 (27.0–34.0) cmH2O, 
whereas for the PRP group were: LPP-preT: 40.5 (33.2–46.3) cmH2O, LPP – postT: 15.7 (3.0–24.0) cmH2O, LPP 
– 1month: 31.6 (24.8–37.4) cmH2O, LPP – 2 months: 36.8 (32.5–45.4) cmH2O. PRP injections on transect-
ed PULs significantly increased LPPs at one month follow-up [31.6 cmH2O vs. 27.3 cmH2O, p = .043].  
This effect was confirmed at two months [36.8 cmH2O vs. 29.0 cmH2O, p <.001].
Conclusions Injection of PRP into transected PULs significantly improved LPPs at one and two months' 
follow-up. However, further experimental and clinical research is needed to evaluate the safety and ef-
ficacy of this treatment, in clinical practice.
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miological study, which included 28,000 women, re-
searchers concluded that urinary leakage is highly 
prevalent. Seven percent of these women reported 
significant incontinence and should be considered 
as potential patients [3]. 
Urinary continence should be regarded as a complex 
dynamic process that involves both the bladder and 
INTRODUCTION
The definition of stress urinary incontinence (SUI) 
is the complaint of involuntary loss of urine on effort 
or physical exertion, or on sneezing or coughing [1]. 
The prevalence of SUI increases with age and affects 
significantly the quality of life [2]. In a large epide-
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restoration over the past decade [10]. PRP consists 
of numerous growth factors, such as vascular endo-
thelial growth factor (VEGF), insulin growth factor 
I (IGF-I), platelet derived growth factor (PDGF), he-
patocyte growth factor (HGF), transforming growth 
factor beta (TGF-b) and fibroblast growth factor 
(FGF). These growth factors play a significant role to 
the pathophysiology of ligament reconstruction [11].
The use of platelet-rich plasma (PRP) injections is 
rapidly growing in clinical practice. Systematic re-
views have concluded that PRP could be considered 
as an effective tendon therapy, with potentially fast-
er recovery and possibly a reduction in injury, with 
no reported adverse reactions. PRP is clinically used 
extensively in orthopedics for musculoskeletal inju-
ries, but also in plastic surgery and dentistry [12]. 
However, to date, these substances have not been in-
vestigated as a potential treatment of female SUI. 
The adhesive, healing, hemostatic and regenerative 
abilities of PRP, [13] might result in the treatment 
of the SUI by restoring the support of the urethra 
and the bladder neck to the pubic bone. In other 
words, if this intervention corrects urethral hyper-
mobility, stress incontinence may resolve, with mini-
mal, if any, complications.
With this background, we recently published our hy-
pothesis [14], which refers to the injection of PRP on 
the PUL, as a possible treatment option for SUI. The 
aim of this study was to evaluate the efficacy of PRP 
on urine leak point pressure (LPP) in an animal ex-
perimental model with transected pubourethral liga-
ments.
MATERIAL AND METHODS
Experimental model
Twenty female nulliparous Sprague-Dawley strain 
rats (12 weeks old) (Hellenic Pasteur Institute, De-
partment of Animal Models for Biomedical Research, 
Greece) were included. The animals were placed in 
weather-controlled chambers (temperature 20°C 
±1°C, humidity 55 ±5%) under controlled lighting 
(12 hours light per day) for 15 days to adapt to their 
new environment. Full nutrient supplementation 
was ensured with the administration of ELVIZ 510 
food pellets. The night before the operation the ani-
mals were fasted from food and water.
The animals had the same characteristics (age, par-
ity, body weight, and were grown under the same en-
vironmental conditions) and were randomly assigned 
into two groups using computer-generated random-
ization. In all animals the PUL was transected. 
In the first group (control group: 10 animals) no in-
tervention was undertaken following PUL transec-
the urethra. According to the integral theory, the 
pubourethral ligament (PUL) is the most impor-
tant anatomical landmark which is associated with 
SUI when injured [4]. The PUL consists of smooth 
muscle, elastin, collagen, nerves and blood vessels. 
This ligament connects the anterior wall of the blad-
der and the proximal urethra to the symphysis pu-
bis. It is divided into the vaginal and the urethral 
part. The urethral part ‘anterior PUL’ inserts into 
the mid-part of the urethra. The vaginal part, ‘poste-
rior PUL’, enters the vagina laterally and posteriorly 
to the urethra, and provides further support [4].
Risk factors associated with SUI, include parity, ag-
ing, menopause, estrogen deficiency, obesity, and 
congenital collagen defects. According to the integral 
theory structure and function are strongly associ-
ated; "Restore the structure, and you will correct the 
function" [4]. 
Several surgical techniques are used for the treat-
ment of SUI. Midurethral slings (MUS) are com-
monly used to correct urethral hypermobility, which 
is presumed to be secondary to PUL defect. A recent 
meta-analysis on the outcomes of the currently used 
surgical procedures for the treatment of female SUI 
[5], concludes that the MUS are the most popular, 
most effective and safer treatment for SUI than oth-
er surgical procedures. However, the MUS are asso-
ciated with intra and post-operative complications, 
such as hemorhage, bladder perforation urethral in-
juries, pain, voiding dysfunction, urinary tract infec-
tions and tape erosion [6].
Urethral bulking agents are a minimally invasive 
alternative approach for the treatment of SUI, es-
pecially in patients suffering from intrinsic sphinc-
ter deficiency and the commonly used synthetic ones 
seem to be safe; although their efficacy remains, to 
date, suboptimal [7]. Restoration of the anatomy 
with autologous agents such as fat has been also pro-
posed to limit the potential side effects of synthetic 
materials; however, one trial in 2001 [8] compared 
periurethral injection of autologous fat with place-
bo injection of saline. The trial was terminated due 
to a death of a participant caused by fat embolism 
a few days following the injection. There was no 
statistically significant difference in the outcome 
measures between the two groups. The poor efficacy 
and the potentially unsafe use of autologous fat in-
jection have this agent from being used as a treat-
ment for SUI.
A recent Cochrane review concludes that at present, 
injection therapy cannot be deemed as a first line 
treatment for women fit for other surgical proce-
dures, due to questionable efficacy [9]. 
Fibrin adhesives and platelet rich plasma (PRP) have 
been extensively investigated in the field of tendon 
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tion. In the second group (study group: 10 animals), 
PRP was applied with pipette, immediately after the 
PUL transection (first phase) and was followed by 
a second application of PRP at one month follow-
up (second phase). According to the wound healing 
cascade, the cellular and matrix proliferation, is the 
most significant phase of healing, begins within days 
of the trauma and lasts from 48 h up to 6 weeks. 
As there is evidence that the application of PRP ac-
celerates wound healing, the second phase of the ex-
periments was performed in one month [15]. 
The LPPs were measured 4 times in total in both 
groups. The first measurement was undertaken be-
fore the PUL transection (LPP – preT), the second 
immediately following the PUL transection and just 
prior to the first PRP application for the PRP group 
(LPP – postT) (first phase) and then at one month 
and just prior to the second PRP application for 
the PRP group (LPP – 1month) (second phase) and 
at two months follow-up (LPP – 2 months) (third 
phase). At each assessment, the LPP was measured 
five times for each rat and the mean value of these 
measurements was calculated to confirm the repeat-
ability of the method.
Description of the surgical technique  
of suprapubic catheter insertion  
and pubourethral ligament transection
The rats were anaesthetized by an intraperitoneal 
injection of ketamine hydrochloride 70 mg/kg and 
of xylazine 6 mg/kg [16]. Our technique was a modi-
fication of the techniques described previously 
by Kefter et al. [17] and Malmgren et al. [18]. A mid-
line suprapubic incision approximately 1 cm long 
was performed in order to gain access to the peri-
toneal cavity. The bladder was identified and was 
held with a pair of atraumatic non-toothed forceps. 
A 20 G catheter was placed on the bladder dome with 
a sharp needle as a guide. Following the LPP mea-
surements, the catheter was removed and the inci-
sion was closed in layers using 5-0 Vicryl (Ethicon) 
for the muscle and 3-0 Vicryl for the skin.
The transection of the pubourethral ligament was 
performed as previously described by Kefter et al. 
[17] in 2009. A reverse Trendelenburg position was 
used and the bladder was pulled superiorly and pos-
teriorly to adequately expose and visualize the ret-
ropubic space. The PUL was identified and sharply 
incised (transected) using a size 11 blade. The PRP 
solution was applied to this region, initially following 
the PUL-transection and the LPP measurements at 
the first phase of the experiments, and the same tech-
nique was followed at the second phase (1 month). 
The bladder was held with atraumatic forceps and 
pulled gently superiorly and posteriorly, whilst 
the PRP was applied suprapubically (Figures 1, 2). 
The same technique was followed in the control 
group. Under anesthesia the bladder was accessed 
transabdominally and catheterized, but PRP was not 
injected.
Leak point pressure measurements technique
The LPPs were measured using a water manometer. 
A 3-way tap with extension lines filled with normal 
saline (N/S 0.9%) and free of air bubbles was used 
to connect the manometer (pressure 0 cmH2O to the 
level of the bladder) to a fluid bag on one side, and to 
Figure 1. Transection of the pubourethral ligament. The blad-
der was held with a pair of atraumatic forceps and gentle trac-
tion was applied superiorly and posteriorly, whilst the PUL was 
transected suprapubically.
Figure 2. The bladder was held with a pair of atraumatic 
forceps, whilst the catheter was inserted through the bladder 
dome using a sharp needle as a guide.
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ures 3, 4). The leakage of urine occurred at bladder 
capacity and the pressure at the time of leakage on 
the manometer scale was documented as LPP, and 
was marked in centimeters of water (cmH2O) [19] 
(Figure 5). This represents the minimal pressure 
in the bladder that resulted in leakage of urine. 
We did not apply external pressure.
Platelet rich plasma (PRP) preparation
Platelet rich plasma was prepared according to 
a standardized research protocol for PRP prepara-
tion in rats published by Messora et al. [16]. The 
maximum blood volume that can be safely removed 
from each rat without fluid replacement, is less than 
1.3 ml for a one time sample [20], therefore, 1.2 ml 
was harvested from each rat with retro-orbital punc-
ture. The blood was collected in 5 ml silicone vac-
uum tubes with 0.13 ml of 10% sodium citrate and 
was initially centrifuged at 160 G, for 20 minutes, 
at room temperature (22°C). Following the centrif-
ugation, two fractions were created. A red fraction 
at the lower part of the tube (from the red cells) and 
an upper straw-yellow turbid fraction (serum com-
ponent). The silicone tube was marked at a point 
1 mm below the line dividing the red with the yel-
low fraction and all the content above this point was 
retrieved by a pipette and transferred to another 
5 ml vacuum tube, in which a line corresponding 
to 0.13 ml was drawn from the tube's bottom. A sec-
ond centrifugation was performed for this sample, 
at 400 G, for 15 minutes, resulting again in two frac-
tions, one above (platelet-poor plasma PPP) and an-
other below the line (PRP). The PPP fraction was 
pipetted and the leftover PRP fraction was kept in 
the silicone vacuum tube and was finally activated 
with 0.07 ml of 10% calcium chloride solution, prior 
to the application. Autologous PRP was harvested 
from each rat. Following blood specimen collection, 
PRP was prepared whilst the rat was in theater for 
catheterization of the bladder. PRP was injected just 
before the application. Hence, there were no con-
cerns of a potential immune response.
Statistical analysis
Statistical significance of the difference of the me-
dian values between groups was analyzed using the 
Mann-Whitney U test due to the non normal dis-
tribution. Differences were considered significant 
at p <0.05. The SPSS statistical package was used 
in this study (IBM Corp. Released 2013 Version 22.0. 
Armonk, NY: IBM Corp.).
Given the absolute lack of previous studies in this 
field, we did not perform sample size calculation for 
the bladder on the other side via a 20 G catheter. The 
extension line of the manometer was free of fluid. 
The 3-way tap was then turned so that it was open 
to the fluid bag (slow flow 1 ml over 3 minutes), 
to the manometer and to the bladder (all directions), 
allowing the manometer column to fill with fluid. 
The fluid level within the manometer column was 
increasing, as a result of continuous increase of the 
intravesical pressure, and the infusion of N/S was 
discontinued at the time of urethral leakage (Fig-
Figure 3. Water manometer. The bladder was at the level  
of the manometer and the relative hydrostatic pressure was 
zero cmH2O. The red ball of the manometer represents the 
intravesical pleasure.
Figure 4. Water manometer. The bladder was at the level  
of the manometer and the relative hydrostatic pressure was 
zero cmH2O. The red ball of the manometer represents the 
intravesical pleasure.
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Figure 5. Water manometer. The bladder was at the level 
of the manometer, the catheter was inserted to the bladder 
dome and the pressure at the time of leakage was document-
ed as leak point pressure.
Figure 7. Control group results. This chart presents the mean 
leak point pressures in cmH2O for each rat in the 4 different 
sets of measurements. Initially before the pubourethral liga-
ment (PUL) transection and following the PUL transection, and 
later at one and two months follow-up. 
Figure 6. Platelet rich plasma group results. This chart pres-
ents the mean leak point pressures in cmH2O for each rat in 
the 4 different sets of measurements. Initially before the pubo-
urethral ligament (PUL) transection and following the PUL 
transection and later at one and two months follow- up.
Figure 8. Median leak point pressures for each group over 
time at 0 before the pubourethral ligament (PUL) transection, 
at 0 post PUL transection and at 1 and 2 months.
from the remaining 19 animals. No differences were 
observed prior to PUL transection and immediately 
after the transection between the 2 groups. 
First phase
The median LPP prior to PUL transection LPP – preT 
for the control group was 35.6 (29.8–44.8) cmH2O 
and for the PRP group 40.5 (33.2–46.3) cmH2O 
(p = 0.353). The median leak point pressure im-
mediately after the PUL transection (LPP – postT) 
for the control group was 14.6 (5.8–19.0) cmH2O and 
for the PRP group 15.7 (3.0–24.0) cmH2O (p = 0.631). 
(Figures 6, 7, 8). Following the measurements of the 
our findings and the number of animals that was used 
was based on the previous study of Kefer et al. [17], 
also accounting for a potential animal loss of 20%. 
RESULTS
Twenty rats were initially included in the study and 
randomly allocated on a 1:1 ratio into two groups. 
One rat in the PRP group died 20 min postoperatively. 
The results of our study are based on the data drawn 
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stem cells in the area, which in turn enhance the de-
position of collagen fibers [21]. 
Previous studies have shown, that transection of 
the PUL causes SUI [17, 22, 23]. It has been dem-
onstrated that the LPP of female rats and intact 
PUL is significantly higher compared to those with 
an incised PUL (16.3 ±2.74 vs. 36.6 ±8.39 cmH2O 
p <0.00001) [24] at 4-days follow-up. The most im-
portant finding of the present study is that the lo-
cal administration of PRP in rats with incised PUL 
leads to significantly increased LPP measurements 
compared to the control group, especially at the 
two-month follow-up. 
Strengths and limitations
Our study evaluated for the first time the impact 
of PRP application in a transected PUL in an ani-
mal experimental model. The experiments were 
performed under repeatable conditions for higher 
precision and accuracy. The LPP measurements 
for each rat were performed under the same condi-
tions of measurement. These conditions include the 
same measurement technique, the same observer, 
the same measurement instruments (same manom-
eter and catheters), the same experimental labora-
tory and the repetition was over the shortest pos-
sible period of time. At each assessment the LPP 
was measured five times for each rat and the mean 
value of these measurements was calculated in order 
to achieve higher accuracy. 
An iatrogenically transected PUL is not a true rep-
resentation of the clinical situation of PUL injury 
where the ligaments are damaged during childbirth. 
Furthermore, in a clinical setting the type of anaes-
thesia may affect the urethral sphincter tone and 
the results may not represent those of non-anaes-
thetized rats. In addition, during the measurement 
of the LPPs, the continuous flow of the normal saline 
that was used, was resulting in continuous increase 
of the bladder pressure, making it impossible to de-
tect or evaluate the presence or absence of bladder 
overactivity. Measuring LPP before and after PUL 
transection would control for such possible confound-
ing. We accepted that the surgical transection of the 
pubourethral ligament itself is unlikely biologically 
to have caused overactive bladder that would con-
found the LPP readings. Also, we did not use flared 
tip catheter for the bladder catheterization and some 
leakage of the fluid might have occurred from the 
point that the catheter was inserted; however we 
did not notice leakage macroscopically. Another lim-
itation is that because of the second application of 
PRP, outcomes at 2 months are difficult to interpret 
as the difference could reflect a long-term effect of 
LPP – postT, PRP was injected only to the rats of the 
PRP group.
Second phase
At 1-month follow-up the LPPs of the animals that 
were injected with PRP were significantly higher 
compared to those of the control group. The median 
Leak Point Pressure 1 month after the pubourethral 
ligament transection (LPP – 1month) for the control 
group was 27.3 (19.2–33.8) cmH2O, whereas for the 
PRP group was 31.6 (24.8–37.4) cmH2O (p = .043).
Immediately following the measurements of the LPP 
at 1 month follow-up, a second application of PRP 
was performed for the PRP group.
Third phase
The observed differences were still significantly higher 
at 2-months follow-up. The median leak point pressure 
2 months after the pubourethral ligament transection 
for the control group was 29.0 (27.0–34.0) cmH2O, 
whereas for the PRP group 36.8 (32.5–45.4) cmH2O 
(p <.001) (Figures 6, 7, 8), (Table 1).
DISCUSSION
Main findings
The findings of our study suggest that PRP may sig-
nificantly restore LPPs after the transection of the 
PUL. SUI can have a significant impact on women's 
quality of life. Application of PRP to a damaged PUL, 
could be a potentially effective treatment option, for 
example for women at the postpartum period. This 
would be a minimally invasive procedure avoiding 
the risks of major interventions and could potential-
ly be performed under local anaesthesia. 
The growth factors found in the PRP, play a signifi-
cant role in the pathophysiology of ligament heal-
ing and reconstruction. Studies have evaluated the 
efficacy of the PRP in tendon and ligament healing 
by enhancing the accumulation of mesenchymal 
Table 1. Results: median pressures in cmH2O
Leak point pressure among groups
Control PRP p-value
LPP – pre 35.6 (29.8–44.8) 40.5 (33.2–46.3) .353
LPP – post 14.6 (5.8–19.0) 15.7 (3.0–24.0) .631
LPP – 1 month 27.3 (19.2–33.8) 31.6 (24.8–37.4) .043
LPP – 2 months 29.0 (27.0–34.0) 36.8 (32.5–45.4) <.001
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Animal models have been previously used to model 
tissue recovery before introducing various surgi-
cal and medical options in clinical practice; hence, 
it may become a useful precursor for future re-
search. Our findings are rather promising; however, 
the pathophysiological processes that take place in 
terms of tissue healing and remodeling have not 
been yet fully elucidated. 
CONCLUSIONS
As pubourethral ligament (PUL) defects have been 
linked to the pathophysiology of stress urinary in-
continence (SUI), the correction of the anatomy 
of this ligament may lead to the treatment of SUI. 
The growth factors play a significant role in the 
process of the restoration of the ligaments and 
platelet rich plasma (PRP) is an easily prepared 
solution, rich in growth factors, which can be ad-
ministered to the damaged ligaments at a low cost. 
The findings of our study suggest that PRP may 
significantly improve leak point pressures (LPP) 
after transection of the PUL. However, further 
experimental and clinical research is needed to 
evaluate the safety and efficacy of this treatment, 
in clinical practice.
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the first treatment, a short-term effect of the second 
treatment or their combination. Also, the amount of 
PRP that was applied was arbitrary, according to the 
maximum harvested material (produced from 1.2 ml 
of autologous blood) and we have not investigated 
the effect of the PRP on a group of rats with intact 
PUL, as well as we did not have a group with intact 
PUL to follow over time.
Despite these limitations, we believe that this study 
has provided valuable information regarding the de-
velopment of PRP treatment for SUI.
Implications for future research
In our study the treatment of PRP started imme-
diately following the PUL injury. Future studies 
should address further the efficacy and safety of PRP 
on female SUI in an experimental and clinical set-
ting. This way, we will be able to evaluate its role and 
effects in humans and further investigate the under-
lying tissue remodeling and ligament restoration. 
Also, to date, there is no clear evidence to support 
the benefit of a repeat application of PRP and the 
timing that this should be reapplied. The reported 
number and frequency of the application varies sig-
nificantly between studies. Studies report outcomes 
with a single application of PRP, or a repeat appli-
cation in 6 weeks, even a multiple application every 
second day until full recovery [25].
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